Top

Published in:

Open Access 01-07-2017 | Original Article

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment

Authors: Gülçin Gezgin, Mehmet Dogrusöz, T. Huibertus van Essen, Wilhelmina G. M. Kroes, Gregorius P. M. Luyten, Pieter A. van der Velden, Vonn Walter, Robert M. Verdijk, Thorbald van Hall, Sjoerd H. van der Burg, Martine J. Jager

Published in: Cancer Immunology, Immunotherapy | Issue 7/2017

Abstract

Uveal melanoma (UM) is characterized by a number of genetic aberrations that follow a certain chronology and are tightly linked to tumor recurrence and survival. Loss of chromosome 3, bi-allelic loss of BAP1 expression, and gain in chromosome 8q have been associated with metastasis formation and death, while loss of chromosome 3 has been associated with the influx of macrophages and T cells. We used a set of genetically-classified UM to study immune infiltration in the context of their genetic evolution. We show in two independent cohorts that lack of BAP1 expression is associated with an increased density of CD3⁺ T cells and CD8⁺ T cells. The presence of extra copies of chromosome 8q in disomy 3 tumors with a normal BAP1 expression is associated with an increased influx of macrophages (but not T cells). Therefore, we propose that the genetic evolution of UM is associated with changes in the inflammatory phenotype. Early changes resulting in gain of chromosome 8q may activate macrophage infiltration, while sequential loss of BAP1 expression seems to drive T cell infiltration in UM.

Kujala E, Makitie T, Kivela T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44:4651–4659CrossRefPubMed

Kaliki S, Shields CL (2016) Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). doi:10.1038/eye.2016.275

Augsburger JJ, Correa ZM, Shaikh AH (2009) Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 148:119–127. doi:10.1016/j.ajo.2009.01.023 CrossRefPubMed

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentral

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373:23–34. doi:10.1056/NEJMoa1504030 CrossRefPubMed

Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384. doi:10.1016/S1470-2045(15)70076-8 CrossRefPubMed

Verdegaal EM (2016) Adoptive cell therapy: a highly successful individualized therapy for melanoma with great potential for other malignancies. Curr Opin Immunol 39:90–95. doi:10.1016/j.coi.2016.01.004 CrossRefPubMed

Bol KF, van den Bosch T, Schreibelt G et al (2016) Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology 123:2265–2267. doi:10.1016/j.ophtha.2016.06.027 CrossRefPubMed

de la Cruz PO Jr, Specht CS, McLean IW (1990) Lymphocytic infiltration in uveal malignant melanoma. Cancer 65:112–115CrossRefPubMed

10.

Whelchel JC, Farah SE, McLean IW, Burnier MN (1993) Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci 34:2603–2606PubMed

11.

de Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, Jager MJ (1996) HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol 234:34–42CrossRefPubMed

12.

Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O (2001) Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci 42:2153–2156PubMed

13.

Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ (2008) Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 49:505–510. doi:10.1167/iovs.07-0786 CrossRefPubMed

14.

Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. The Lancet 347:1222–1225CrossRef

15.

Coupland SE, Lake SL, Zeschnigk M, Damato BE (2013) Molecular pathology of uveal melanoma. Eye (Lond) 27:230–242. doi:10.1038/eye.2012.255 CrossRef

16.

Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, Douglas A, Howard P (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114:1925–1931. doi:10.1016/j.ophtha.2007.06.012 CrossRefPubMed

17.

Cassoux N, Rodrigues MJ, Plancher C et al (2014) Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. Br J Ophthalmol 98:769–774. doi:10.1136/bjophthalmol-2013-303867 CrossRefPubMed

18.

Singh AD, Tubbs R, Biscotti C, Schoenfield L, Trizzoi P (2009) Chromosomal 3 and 8 status within hepatic metastasis of uveal melanoma. Arch Pathol Lab Med 133:1223–1227. doi:10.1043/1543-2165-133.8.1223 PubMed

19.

de Lange MJ, van Pelt SI, Versluis M et al (2015) Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma. Oncotarget 6:37824–37835. doi:10.18632/oncotarget.5637 CrossRefPubMedPubMedCentral

20.

Versluis M, de Lange MJ, van Pelt SI, Ruivenkamp CA, Kroes WG, Cao J, Jager MJ, Luyten GP, van der Velden PA (2015) Digital PCR validates 8q dosage as prognostic tool in uveal melanoma. PLoS One 10:e0116371. doi:10.1371/journal.pone.0116371 CrossRefPubMedPubMedCentral

21.

Tschentscher F, Husing J, Holter T et al (2003) Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 63:2578–2584PubMed

22.

Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64:7205–7209. doi:10.1158/0008-5472.can-04-1750 CrossRefPubMedPubMedCentral

23.

Harbour JW, Onken MD, Roberson ED et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410–1413. doi:10.1126/science.1194472 CrossRefPubMedPubMedCentral

24.

Koopmans AE, Verdijk RM, Brouwer RW et al (2014) Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol 27:1321–1330. doi:10.1038/modpathol.2014.43 CrossRefPubMed

25.

Kalirai H, Dodson A, Faqir S, Damato BE, Coupland SE (2014) Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br J Cancer 111:1373–1380. doi:10.1038/bjc.2014.417 CrossRefPubMedPubMedCentral

26.

van Essen TH, van Pelt SI, Versluis M et al (2014) Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol 98:1738–1743. doi:10.1136/bjophthalmol-2014-305047 CrossRefPubMedPubMedCentral

27.

Fang Y, Fu D, Shen XZ (2010) The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta 1806:1–6. doi:10.1016/j.bbcan.2010.03.001 PubMed

28.

Karim R, Tummers B, Meyers C et al (2013) Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte’s innate immune response. PLoS Pathog 9:e1003384. doi:10.1371/journal.ppat.1003384 CrossRefPubMedPubMedCentral

29.

Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP, Jager MJ (2011) Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 52:643–650. doi:10.1167/iovs.10-5979 CrossRefPubMed

30.

Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH, Jager MJ (2012) Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci 53:5370–5378. doi:10.1167/iovs.11-9280 CrossRefPubMed

31.

Ly LV, Bronkhorst IH, van Beelen E, Vrolijk J, Taylor AW, Versluis M, Luyten GP, Jager MJ (2010) Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci 51:5445–5451. doi:10.1167/iovs.10-5526 CrossRefPubMedPubMedCentral

32.

Bronkhorst IH, Jehs TM, Dijkgraaf EM, Luyten GP, van der Velden PA, van der Burg SH, Jager MJ (2014) Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma. JAMA Ophthalmol. 132: 614–621. doi:10.1001/jamaophthalmol.2014.43

33.

van den Bosch T, Koopmans AE, Vaarwater J, van den Berg M, de Klein A, Verdijk RM (2013) Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance. Invest Ophthalmol Vis Sci 54:7354–7361. doi:10.1167/iovs.13-12407 CrossRefPubMed

34.

McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, Shapero MH, de Bakker PIW, Maller JB, Kirby A, Elliott AL, Parkin M, Hubbell E, Webster T, Mei R, Veitch J, Collins PJ, Handsaker R, Lincoln S, Nizzari M, Blume J, Jones KW, Rava R, Daly MJ, Gabriel SB, Altshuler D (2008) Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 40(10):1166–1174CrossRefPubMed

35.

Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12(4):R41CrossRefPubMedPubMedCentral

36.

Van Raamsdonk CD, Griewank KG, Crosby MB et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363:2191–2199. doi:10.1056/NEJMoa1000584 CrossRefPubMedPubMedCentral

37.

Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49:5230–5234. doi:10.1167/iovs.08-2145 CrossRefPubMedPubMedCentral

38.

Singh N, Singh AD, Hide W (2015) Inferring an Evolutionary Tree of Uveal Melanoma From Genomic Copy Number Aberrations. Invest Ophthalmol Vis Sci 56:6801–6809. doi:10.1167/iovs.15-16822 CrossRefPubMed

39.

Royds JA, Sharrard RM, Parsons MA, Lawry J, Rees R, Cottam D, Wagner B, Rennie IG (1992) C-myc oncogene expression in ocular melanomas. Graefes Arch Clin Exp Ophthalmol 230:366–371CrossRefPubMed

40.

Parrella P, Caballero OL, Sidransky D, Merbs SL (2001) Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Invest Ophthalmol Vis Sci 42:1679–1684PubMed

41.

Borrello MG, Degl’Innocenti D, Pierotti MA (2008) Inflammation and cancer: the oncogene-driven connection. Cancer Lett 267:262–270. doi:10.1016/j.canlet.2008.03.060 CrossRefPubMed

42.

De Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, Danen EH, Jager MJ (1995) Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 62:155–161CrossRefPubMed

43.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. doi:10.1038/nature07205 CrossRefPubMed

44.

Li L, Tao Q, Jin H et al (2010) The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res 16:2949–2958. doi:10.1158/1078-0432.ccr-09-3178 CrossRefPubMed

45.

Yang L, Karin M (2014) Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ 21:1677–1686. doi:10.1038/cdd.2014.131 CrossRefPubMedPubMedCentral

46.

Wiesner T, Murali R, Fried I, Cerroni L, Busam K, Kutzner H, Bastian BC (2012) A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 36:818–830. doi:10.1097/PAS.0b013e3182498be5 CrossRefPubMedPubMedCentral

47.

Liu J, Li F, Ping Y et al (2015) Local production of the chemokines CCL5 and CXCL10 attracts CD8 + T lymphocytes into esophageal squamous cell carcinoma. Oncotarget 6:24978–24989. doi:10.18632/oncotarget.4617 CrossRefPubMedPubMedCentral

48.

Li H, Alizadeh H, Niederkorn JY (2008) Differential expression of chemokine receptors on uveal melanoma cells and their metastases. Invest Ophthalmol Vis Sci 49:636–643. doi:10.1167/iovs.07-1035 CrossRefPubMed

49.

Li H, Yang W, Chen PW, Alizadeh H, Niederkorn JY (2009) Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases. Invest Ophthalmol Vis Sci 50:5522–5528. doi:10.1167/iovs.09-3804 CrossRefPubMedPubMedCentral

50.

Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523:231–235. doi:10.1038/nature14404 CrossRefPubMed

51.

Zuidervaart W, Pavey S, van Nieuwpoort FA, Packer L, Out C, Maat W, Jager MJ, Gruis NA, Hayward NK (2007) Expression of Wnt5a and its downstream effector beta-catenin in uveal melanoma. Melanoma Res 17:380–386. doi:10.1097/CMR.0b013e3282f1d302 CrossRefPubMed

52.

Vu TH, Bronkhorst IH, Versluis M, Marinkovic M, van Duinen SG, Vrolijk J, Luyten GP, Jager MJ (2013) Analysis of inflammatory cells in uveal melanoma after prior irradiation. Invest Ophthalmol Vis Sci 54:360–369. doi:10.1167/iovs.12-9424 CrossRefPubMed

53.

Dogrusoz M, Kroes WG, van Duinen SG, Creutzberg CL, Versluis M, Bleeker JC, Marinkovic M, Luyten GP, Jager MJ (2015) Radiation treatment affects chromosome testing in uveal melanoma. Invest Ophthalmol Vis Sci 56:5956–5964. doi:10.1167/iovs.15-17092 CrossRefPubMed

Title: Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment
Authors: Gülçin Gezgin
Mehmet Dogrusöz
T. Huibertus van Essen
Wilhelmina G. M. Kroes
Gregorius P. M. Luyten
Pieter A. van der Velden
Vonn Walter
Robert M. Verdijk
Thorbald van Hall
Sjoerd H. van der Burg
Martine J. Jager
Publication date: 01-07-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 7/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-1991-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2017

A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia

Coexpressed modular gene expression reveals inverse correlation between immune responsive transcription and aggressiveness in gastric tumours

Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow “in situ tumor vaccination”?

Professor Enrico Mihich, 1928–2016

IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma

Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer